Try the modernized beta website. Learn more about the modernization effort.
Working… Menu

A Phase 1/2 Safety Study of Intratumorally Dosed INT230-6 (IT-01)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03058289
Recruitment Status : Active, not recruiting
First Posted : February 20, 2017
Last Update Posted : June 27, 2022
Merck Sharp & Dohme LLC
Bristol-Myers Squibb
Information provided by (Responsible Party):
Intensity Therapeutics, Inc.

No Study Results Posted on for this Study
Recruitment Status : Active, not recruiting
Estimated Primary Completion Date : July 2022
Estimated Study Completion Date : October 2023